Standard Keytruda Dosing Schedules
Keytruda (pembrolizumab) is approved with multiple dosing options depending on the cancer type, patient weight, and treatment goal. The primary schedules are:
- Fixed 200 mg every 3 weeks (Q3W): Used for most adults across indications like melanoma, non-small cell lung cancer (NSCLC), and head and neck squamous cell carcinoma. Administered intravenously over 30 minutes.[1][2]
- Fixed 400 mg every 6 weeks (Q6W): An alternative for adults, equivalent in exposure to the 200 mg Q3W schedule. Approved for the same indications to offer flexibility, such as fewer clinic visits. Not recommended for certain pediatric uses or when rapid tumor response is critical.[1][3]
- Weight-based 2 mg/kg every 3 weeks: Applied in specific cases like pediatric patients (over 26 months for some cancers) or certain adult regimens, capped at 200 mg. Common in microsatellite instability-high (MSI-H) cancers or combined therapies.[1][2]
Dosing starts on day 1 of each cycle and continues for up to 2 years or until disease progression/toxicity, varying by indication (e.g., 35 cycles for NSCLC adjuvant therapy).[1]
How Dosing Differs by Cancer Type
Schedules align with FDA approvals:
- NSCLC: 200 mg Q3W or 400 mg Q6W with chemotherapy; weight-based in some combos.[1]
- Melanoma: 200 mg Q3W or 400 mg Q6W, alone or with other drugs.[1]
- Triple-negative breast cancer: 200 mg Q3W with chemo.[1]
- Adjustments occur for renal/hepatic impairment (none needed) or body weight extremes.[2]
Physicians select based on trial data showing similar efficacy/safety between Q3W and Q6W.[3]
Switching Between Schedules
Patients can switch from 200 mg Q3W to 400 mg Q6W mid-treatment if clinically appropriate, as exposures match in population studies. No washout period required, but timing aligns to maintain steady-state levels (e.g., next dose at 6-week mark). Not all switches are supported—consult prescribing info.[1][3]
Pediatric and Special Populations
Kids under 30 kg get 2 mg/kg Q3W (max 200 mg). Q6W not approved for pediatrics. Dose reductions for toxicity (e.g., 50% for grade 2+ immune effects) or holds for severe reactions.[1][2]
Why Multiple Schedules Exist
Q6W was added in 2020 based on pharmacokinetic modeling and trials (e.g., KEYNOTE-051) confirming non-inferiority to Q3W, addressing patient convenience and pandemic-related visit reductions. No efficacy differences in overall survival across schedules.[3][4]
[1]: Keytruda Prescribing Information (FDA, latest 2024)
[2]: Merck Keytruda Dosing Guide
[3]: FDA Approval Summary for Q6W Dosing (2020)
[4]: KEYNOTE Trials Pharmacokinetics Data